Anthony Nolan – Our Stories

Saving the Lives of People with Blood Cancer

  • Home
  • Patient Services & Insight
  • Supporter Stories
  • Science & Policy
  • Donor Stories

Share this:

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)

What factors should you consider when identifying a cell source provider?

Katie GriffeeDecember 17, 2020 by Katie Griffee Leave a Comment

Through the Anthony Nolan Cell & Gene Therapy Service’s provision of cellular material to cell and gene therapy researchers, we are familiar with industry standards and clients’ requirements. But we wanted to find out more about what drives decision making when selecting a cell source provider, and set out the key questions you should be asking.  

So we conducted a poll with leaders in the cell and gene therapy industry to find out what mattered to them…

Quality and availability

The most common challenges identified in obtaining cell material were quality and availability. In particular, the majority of respondents (77%) said that access to high-quality cell sources would actually expedite their developments.

The opportunity to accelerate R&D is of crucial importance in the cell and gene therapy space, where progress is rapid and there are increasing numbers of organisations competing.

Bespoke materials

When asked what factors are important when identifying a cell source provider, the most common answers were:

  • Defined cell specifications
  • Standardisation of process
  • Managed logistics

This tells us that clients feel that getting bespoke material provided to specification is of the utmost importance. In contrast, only 5% said that availability/access to off-the-shelf frozen material was of interest.

Researchers also selected location as important i.e. whether the material is locally sourced, as well as price.

Ethically sourced

15% of respondents said that a deciding factor is whether material was ethically-sourced.  This is a unique consideration for organisations working in cell and gene therapy, compared with traditional pharma manufacturing. As the cell and gene therapy space has become more established, we’ve seen more clients scrutinising ethics to ensure that the effort of the donor is proportionate to the potential patient benefit.

Asking the right questions

A cell source provider should meet all of the above requirements, without having to consider a trade-off e.g. between ethics and price.

That’s why it’s really important to ask the right questions to help you identify a partner that meets your needs:

  • How do you procure material? Do you use any third parties?
  • How can you provide material to my specifications?
  • Are donors paid for donations?
  • Are appropriate ethics considerations in place? Does this meet regulations in the country where the material will be delivered?
  • What processes are in place to ensure that cells are ethically sourced?
  • Will I have full visibility on the donor consent?
  • Do you have experience in providing material to researchers?
  • What are the long-term implications of working together – from early stage research through to clinical application?

Ultimately, we believe that you need to find a partner that is aligned exactly to your core mission: to improve the lives of patients through the development of cell and gene therapies.

Related

Share this:

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)

Filed Under: Cell & Gene Therapy

Katie Griffee

Katie Griffee

Katie Griffee is the Business Development manager of Anthony Nolan Cell and Gene Therapy Services. She has a background in Biomedical Sciences and several years’ experience in the pharmaceutical industry. Her aim is to boost awareness of the Cell and Gene Therapy Services and foster new client relationships – to support the research and development of new therapies that have the potential to improve and save patients’ lives.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent News

What factors should you consider when identifying a cell source provider?

December 17, 2020 by Katie Griffee

HENNY BRAUND: WHAT DOES THE FUTURE HOLD FOR STEM CELL TRANSPLANT RECIPIENTS?

November 24, 2020 by Henny Braund

How can we personalise care in the digital era?

November 3, 2020 by Nusha Haghpanah

‘I was 6 months pregnant when I was told I needed a bone marrow transplant’ – Sophie’s story

November 3, 2020 by Clare McCrudden

Launching our report: Stem cell transplants and COVID-19: What have we learnt from patients during the pandemic?

October 29, 2020 by Charlotte Wickens

Post categories

  • Cell & Gene Therapy
  • Cord blood
  • Donor Stories
  • Patient Services & Insight
  • Science & Policy
  • Scientific Research
  • Supporter Stories
  • Uncategorized

Enter your email address to subscribe to this blog and get new posts via email

Links

  • Home
  • Patient Services & Insight
  • Supporter Stories
  • Science & Policy
  • Donor Stories

Follow Us

Terms & Conditions

Privacy Policy and Cookies

Anthony Nolan is a registered charity no 803716/SC038827 and a registered company no 2379280

© 2021 Anthony Nolan · anthonynolan.org